Reaxys Announces Winners of the 2012 Reaxys PhD Prize
The Reaxys PhD Prize awards original and innovative research in organic, organometallic and inorganic chemistry
Neuchâtel, Switzerland, June 19, 2012 - Reaxys announces the winners of the Reaxys PhD Prize. Awarding innovative and original research in organic, organometallic and inorganic chemistry, the Reaxys PhD Prize celebrates the top research being performed by leading young chemists across the globe.
The 2012 Reaxys PhD Prize Winners are:
- Gregory Hamilton at University of California, Berkeley USA
- Debashis Mandal at Nagoya University, Japan
- Craig Stivala, University of California, Santa Barbara, USA
The winners have been selected from 45 finalists (see http://prize.reaxys.com/ for details of all the finalists) by the Chairs of the Review Board: Professors Tony Barrett (Imperial College, UK), Barry Trost (Stanford, USA) and Henry Wong (Chinese University Hong Kong, China).
Professor Wong said, “The prize goes from strength to strength. The three winners feel very proud to have been selected from such a strong and diverse field of applicants. I am personally very pleased to see such a diverse set of chemistries represented. This year there were a significant number of inorganic and organometallic submissions in addition to the usual strong organic submissions. I am sure that all of these young chemists have extremely bright futures ahead of them.”
Launched in January 2010 the Reaxys PhD Prize has received over 900 submissions from well over 400 of the world’s top chemistry institutions. This year a record 350 submissions were received from 39 countries. Submissions consisted of a representative peer-reviewed piece of published research, PhD supervisor’s recommendation letter and a CV. Entries were closely scrutinized by a review board of over 80 international chemists from academia and industry. The reviewers judged the entries for originality, innovation, importance to the field, applicability, rigor of approach and publication quality.
The three winners and 42 other finalists have each been invited to attend the Reaxys PhD Prize Symposium at the 244th American Chemical Society Meeting in Philadelphia, on Sunday August 19 2012. The winners are invited to give an oral presentation of their research, and the finalists will participate in a special poster session and reception. The symposium will also feature presentations from Professors Martin Jansen (Max-Planck, Stuttgart, Germany) and Barry Trost (Stanford, USA).
To learn more about the Reaxys PhD Prize please visit http://prize.reaxys.com.
To learn more about Reaxys® please visit www.reaxys.com. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.
# # #
Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. For more information please visit https://www.reaxys.com/info/.
Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA and used under license.
About Reed Elsevier Properties SA
Reed Elsevier Properties SA is a centre of excellence within Reed Elsevier for the management, development and protection of intellectual property. Reed Elsevier Properties SA owns the PharmaPendium and Reaxys databases. Trademarks including Reaxys®, PharmaPendium®, Targetinsights™, The Lancet® and World Travel Market® are owned and protected by Reed Elsevier Properties SA and used under licence.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Vice President, Global Corporate Relations, Elsevier
+1 215 239 3508